Kiniksa Pharmaceuticals, Ltd. provided revenue guidance for 2023. Kiniksa now expects 2023 ARCALYST net product revenue of between $220 million and $230 million compared to prior guidance of between $200 million and $215 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.58 USD | +0.26% | -2.05% | +11.63% |
04-23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
04-23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.63% | 1.39B | |
+5.66% | 111B | |
+11.23% | 105B | |
-12.15% | 22.34B | |
-2.74% | 21.93B | |
-6.17% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023